title: Controversies in IgG replacement therapy in patients with antibody deficiency diseases.
abstract: This Current perspectives article will review and highlight the importance of accurate diagnosis of patients who have failed to produce specific antibodies to naturally encountered foreign proteins or polysaccharides or after vaccination and the appropriate institution of immunoglobulin replacement therapy. The field of primary immunodeficiency disease (PIDD) has expanded remarkably since the early descriptions 6 decades ago. With greater recognition and advanced cellular and molecular diagnostic technology, new entities and single-gene defects in patients with PIDD are rapidly being defined. This, combined with treatment advances and newborn screening for severe combined immunodeficiency, has resulted in improved outcomes and survival and even permanent cures. Awareness of PIDD has also increased, but the guidelines for recognition remain to be validated. The zeal for registering and enrolling patients has potentially created a large body of "patients" treated with immunoglobulin replacement unnecessarily. The complexity, diversity, and availability of laboratory testing have brought awareness of PIDD to the forefront, but because of an absence of standardization of certain assays, concerns about the correct diagnosis and appropriate treatment have increased. We hope to refocus the discussion on identifying clear laboratory and clinical guidelines for the establishment of an accurate diagnosis of antibody deficiency, its rationale, and, where indicated, institution of safe treatment.
authors.affiliation: Division of Cell Biology, Department of Pediatrics, National Jewish Health, Denver, CO, USA.
authors.forename: Erwin W
authors.initials: EW
authors.lastname: Gelfand
authors.forename: Hans D
authors.initials: HD
authors.lastname: Ochs
authors.forename: William T
authors.initials: WT
authors.lastname: Shearer
mesh_terms: D017074:Common Variable Immunodeficiency / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology / Q000627:therapeutic use*; D007231:Infant, Newborn; D017410:Practice Guidelines as Topic; D016511:Severe Combined Immunodeficiency / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*
chemical_list: D016756:Immunoglobulins, Intravenous